Cara Therapeutics | CARA - PE Price to Earnings


Cara Therapeutics reported 27.77 in PE Price to Earnings for its fiscal quarter ending in September of 2021.





Pe Change Date
Acadia Pharmaceuticals 10.08 1.53 Mar/2026
Cara Therapeutics 27.77 117.09 Sep/2021
Chugai Pharma 28.87 2.38 Mar/2026
Cipla 23.56 4.18 Mar/2026
Clal Biotechnology 11.67 2.62 Dec/2022
Compugen 4.06 75.75 Dec/2025
CSL 16.16 9.59 Dec/2025
Grifols 11.2 1.08 Dec/2025
Halozyme Therapeutics 11.35 11.8 Mar/2026
J&J 24.53 0.91 Mar/2026
Neurocrine Biosciences 28.09 807.38 Mar/2026
Pacira 38.58 14.1 Mar/2026
Pfizer 9.32 5.16 Mar/2026
RedHill Biopharma 0.04 0.03 Jun/2025
Supernus Pharmaceuticals 44.21 66.17 Mar/2026
Vanda Pharmaceuticals 16.79 7.07 Jun/2023